Dungan, K M <br/><br/>
A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).  [electronic resource] 

 -  Diabetes, obesity & metabolism  May 2016 
 - 475-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12634  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Diabetes Mellitus, Type 2--blood<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Resistance<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Glucagon-Like Peptide-1 Receptor--metabolism<br/>Glucagon-Like Peptides--administration & dosage<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemia--chemically induced<br/>Hypoglycemic Agents--administration & dosage<br/>Immunoglobulin Fc Fragments--administration & dosage<br/>Injections, Subcutaneous<br/>Intention to Treat Analysis<br/>Male<br/>Middle Aged<br/>Patient Dropouts<br/>Recombinant Fusion Proteins--administration & dosage<br/>Sulfonylurea Compounds--adverse effects<br/>Glucagon-Like Peptide-1 Receptor Agonists